Clinical trials: 5-FU
Nasopharyngeal Carcinoma
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant…
- Trial name
- NCT00379262
- Testing
- Capecitabine, Adjuvant chemotherapy using PF (5-Fluorouracil ), Induction chemotherapy using PF (5-Fluorouracil)
- Where
- 7 sites in China
- Volunteers
- 803 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Kidney Cancer
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells.
- Trial name
- NCT00003664
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cancer Biotherapy Research Group
Colorectal Neoplasms
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
To determine the rate of response and duration of reponse following therapy with Aroplatin in subjects with advanced colorectal cancer resistant to standard therapies.
- Trial name
- NCT00043199
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Pancreatic Cancer Resectable, Pancreatic Cancer Stage II
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma…
- Conditions
- Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy, Elderly
- Trial name
- PEACE (NCT06868693)
- Testing
- Neoadjuvant Chemotherapy (NAT) Group
- Volunteers
- 240 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT03775265
- Testing
- Atezolizumab, Biopsy of Bladder, Cisplatin
- Where
- 365 sites in United States
- Volunteers
- 475 people
- Sponsor
- National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
This randomized pilot clinical trial studies the side effects of giving paricalcitol together with fluorouracil and radiation therapy in treating patients with rectal cancer that can be removed in surgery.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT01197664
- Testing
- paricalcitol, radiation therapy, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased…
- Trial name
- HLX07Ib/II (NCT03577704)
- Testing
- HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Henlius Biotech
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in…
- Trial name
- NCT00388700
- Testing
- GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab
- Where
- 4 sites in Israel
- Sponsor
- Galectin Therapeutics Inc.
Breast Cancer
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of…
- Trial name
- NCT00950300
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 106 sites in Argentina, Brazil and 24 more
- Volunteers
- 596 people
- Sponsor
- Hoffmann-La Roche
Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA).
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
- Trial name
- NeoTISLEGA (NCT07059299)
- Testing
- Tislelizumab, FLOT Chemotherapy
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Rectal Cancer
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
Preoperative radiation and chemotherapy is the standard treatment for local advanced rectal cancer. The addition of oxaliplatin to capecitabine combined with radiotherapy does not improve local control and long-term survival.
- Trial name
- NCT03671252
- Testing
- FOLFOXIRI, XELOX, Chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 776 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable hepatic metastases
- Trial name
- NCT00202787
- Testing
- FOLFOX-4+cetuximab, FOLFOX-4
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Breast Cancer
Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
This is a phase IV, prospective, single-center, open-label, randomized, controlled study. Eligible patients are randomly assigned into three groups.
- Trial name
- NCT01199432
- Testing
- 5-FU（intravenous infusion）+epirubicin+cyclophosphamide, 5-FU（intravenous bolus）+epirubicin+cyclophosphamide, epirubicin+cyclophosphamide
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Tao OUYANG
Metastatic Pancreatic Adenocarcinoma
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in…
- Trial name
- COMBAT (NCT02826486)
- Testing
- BL-8040, Pembrolizumab, Chemotherapy
- Where
- 31 sites in United States, Israel and 2 more
- Volunteers
- 80 people
- Sponsor
- BioLineRx, Ltd.
Recurrent Pterygium of Eye, Steroid-Induced Glaucoma
Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
The objective of this study was to evaluate the efficacy of topical 0.2% loteprednol etabonate, a 'soft steroid', compared with topical 0.1% dexamethasone, which is widely used in postoperative pterygium excision to prevent the…
- Trial name
- NCT04075227
- Testing
- 0.2% loteprednol etabonate, 0.1% dexamethasone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Wannisa Suphachearabhan
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002551
- Testing
- fluorouracil, leucovorin calcium, levamisole hydrochloride
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 1,917 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Gastric Cancer
Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer
The primary objective is to determine the tumor response rate of bi-weekly docetaxel plus 24-hour infusion of high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.
- Trial name
- NCT00155883
- Testing
- Taxteral, 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.